Why Tesamorelin Is Suddenly Everywhere in Canada
Tesamorelin spent most of its life as a niche prescription product that few people outside one clinical specialty had heard of. Over the past year, Canadian search interest has climbed sharply, and the compound now turns up in conversations about body composition, visceral fat and growth hormone research that it rarely featured in before.
The Canadian part of that story is more interesting than most people realise, because tesamorelin is, in a real sense, a Canadian compound.
A Compound Discovered in Canada
Tesamorelin was developed by Theratechnologies, a pharmaceutical company based in Montreal. It was first approved in the United States in 2010, under the brand name Egrifta, for a narrow indication: reducing excess abdominal fat in adults living with HIV who have lipodystrophy.
Health Canada followed in April 2014, issuing a Notice of Compliance for the same use, with the indication limited to patients whose excess visceral fat had been confirmed by imaging. At the time the company described it as a drug discovered and developed in Canada, approved by Canadian regulators.
That approval did not translate into a long commercial presence here. Health Canada’s records show the Canadian product listings for Egrifta were discontinued in 2022 and 2023. In other words, the compound Canada produced is no longer marketed as a prescription product in Canada.
What Tesamorelin Actually Is
Tesamorelin is a synthetic analogue of growth hormone releasing hormone, or GHRH. It acts on the pituitary to stimulate the release of the body’s own growth hormone, which in turn raises IGF-1.
What distinguishes it from older GHRH analogues is stability. Tesamorelin carries a modification that protects it from rapid enzymatic breakdown, giving it a longer working window than native GHRH. It sits in the same broad family as the compounds discussed in CJC-1295 and Ipamorelin, but with a much larger body of human clinical data behind it.
How It Differs From Growth Hormone Itself
Because tesamorelin raises growth hormone, it is sometimes discussed as if it were a substitute for growth hormone. Mechanistically, the two are quite different.
Recombinant growth hormone, such as Ziotropin HGH, supplies the hormone directly. Tesamorelin supplies a signal, and the pituitary decides how much growth hormone to release in response. That means the body’s own feedback systems stay involved: growth hormone release still follows a pulsatile pattern, and rising IGF-1 still feeds back on the pituitary.
That distinction is one reason GHRH analogues attract research interest in the first place. They act upstream, preserving more of the natural regulation, whereas direct growth hormone bypasses it. It also means the response to tesamorelin depends on the pituitary’s own capacity, which is not true of growth hormone supplied from outside.
Why Interest Has Grown So Quickly
Several things appear to have converged.
The GLP-1 conversation. Interest in compounds that affect body composition has risen enormously with the attention on GLP-1 receptor agonists. Tesamorelin has been pulled into that conversation as a compound with a distinct mechanism and a specific association with visceral fat, which is covered alongside other compounds in Fat Loss Peptides.
Visceral fat as a research target. Visceral fat, the fat stored around the abdominal organs, has drawn growing research attention as a metabolic marker distinct from overall body weight. Tesamorelin is one of very few compounds with trial data focused specifically on it.
A real clinical record. Most research peptides have thin human data. Tesamorelin has randomised controlled trials behind its original approval, which makes it unusually citable in a field where much of the literature is preclinical.
Supply and visibility. As the prescription product left the Canadian market, the compound became more visible in the research supply channel than in the pharmacy one.
What the Trial Data Shows
The trials that supported approval reported reductions in visceral adipose tissue over 26 weeks in the specific population studied. Several points are worth keeping in view.
| Finding | Context |
|---|---|
| Reduced visceral fat | In adults with HIV-associated lipodystrophy, measured by CT scan |
| Raised IGF-1 | Consistent with its GHRH mechanism |
| Limited effect on body weight | The approved product was described as weight-neutral |
| Effects reversed after stopping | Visceral fat tended to return when treatment ended |
That last row matters. The trial population, the endpoint and the duration were all specific, and the findings cannot simply be extended to other groups or other goals.
The Gaps
Outside that population, the evidence base is much thinner. There is limited published data on tesamorelin in people without HIV-associated lipodystrophy, and the research interest now attached to it is running ahead of what has been formally studied.
Raising growth hormone and IGF-1 also carries effects of its own. The clinical literature records changes in glucose handling and fluid retention, and IGF-1’s role in cell growth is the reason long-term questions remain open.
Where It Sits in the Catalogue
Northern Peptides carries Tesamorelin 10mg as a research compound, and growth hormone research more broadly is grouped under Muscle Growth Peptides. Handling follows the standard lyophilised-peptide approach set out in the reconstitution and storage guide.
The regulatory position for research peptides in Canada, including what changed this year, is covered in Peptide Regulations in Canada.
The Canadian origin also explains some of the search interest. Tesamorelin is one of very few compounds in the research catalogue with a Canadian regulatory history, which makes it a natural point of reference in Canadian discussions about growth hormone research and its regulation.
The Short Version
Tesamorelin is a GHRH analogue developed in Montreal, approved by Health Canada in 2014 for visceral fat in a specific HIV population, and later discontinued as a Canadian prescription product. Its recent visibility comes from the wider body-composition conversation, its unusually solid trial record and its association with visceral fat. The evidence is strongest exactly where it was originally studied, and much thinner everywhere else. Further questions are answered in the FAQ.
All products available through Northern Peptides are sold strictly for research purposes only. Nothing in this article constitutes medical advice, and no compound referenced here is approved by Health Canada for human therapeutic use. Researchers are responsible for ensuring their use of any compound complies with applicable laws and institutional guidelines.
